STRATA Skin Sciences' Q2 Loss Widens Amid Revenue Decline

TL;DR

**SSKN is bleeding cash and losing money, avoid this stock until they can prove a path to profitability.**

AI Summary

STRATA Skin Sciences, Inc. (SSKN) reported a significant decline in financial performance for the three and six months ended June 30, 2025. Net revenues decreased to $7.663 million for the three months ended June 30, 2025, down from $8.435 million in the prior year, representing a 9.0% decrease. For the six months ended June 30, 2025, net revenues were $14.475 million, a 4.7% decrease from $15.189 million in the same period of 2024. The company's net loss widened substantially, reaching $2.489 million for the three months ended June 30, 2025, compared to a net loss of $0.099 million in the prior year. The six-month net loss was $4.921 million, an increase from $3.467 million in 2024. Operating expenses increased by 19.5% to $6.530 million for the three months ended June 30, 2025, primarily due to higher selling and marketing expenses ($3.533 million) and general and administrative expenses ($2.911 million). Cash and cash equivalents decreased from $7.261 million at December 31, 2024, to $5.966 million at June 30, 2025. The company also noted ongoing risks from global supply chain disruptions, the Russia-Ukraine War impacting noble gas supplies, and potential impacts from Middle East conflicts and increased tariffs.

Why It Matters

STRATA Skin Sciences' deteriorating financial performance, marked by declining revenues and a widening net loss, signals significant challenges for investors. The company's inability to grow revenue while operating expenses climb suggests a struggle with cost control and market penetration, particularly with 844 XTRAC systems placed in the US. This could impact employee morale and job security, especially if cost-cutting measures become necessary. For customers, a financially weaker company might mean reduced investment in product development or customer service. In a competitive medical technology market, SSKN's struggles could allow rivals to gain market share, further pressuring the company's long-term viability.

Risk Assessment

Risk Level: high — The company reported a net loss of $2.489 million for the three months ended June 30, 2025, a significant increase from $0.099 million in the prior year. Total stockholders' equity plummeted from $4.972 million at December 31, 2024, to $0.308 million at June 30, 2025, indicating a precarious financial position and potential going concern issues.

Analyst Insight

Investors should consider divesting SSKN shares due to the substantial widening of net losses and the sharp decline in stockholders' equity. The company's inability to generate positive cash flow from operations, with $2.491 million used in the first six months of 2025, suggests a high risk of further capital erosion.

Financial Highlights

debt To Equity

98.74

revenue

$7.663M

operating Margin

-28.9%

total Assets

$30.722M

total Debt

$15.270M

net Income

-$2.489M

eps

-$1.18

gross Margin

56.2%

cash Position

$5.966M

revenue Growth

-9.0%

Key Numbers

• $7.663M — Net Revenues (Q2 2025) (Decreased from $8.435M in Q2 2024, a 9.0% decline.)
• $14.475M — Net Revenues (Six Months 2025) (Decreased from $15.189M in Six Months 2024, a 4.7% decline.)
• $2.489M — Net Loss (Q2 2025) (Widened significantly from $0.099M in Q2 2024.)
• $4.921M — Net Loss (Six Months 2025) (Increased from $3.467M in Six Months 2024.)
• $6.530M — Total Operating Expenses (Q2 2025) (Increased from $5.463M in Q2 2024, a 19.5% rise.)
• $5.966M — Cash and Cash Equivalents (June 30, 2025) (Decreased from $7.261M at December 31, 2024.)
• $0.308M — Total Stockholders' Equity (June 30, 2025) (Significantly down from $4.972M at December 31, 2024.)
• 4,171,161 — Shares Outstanding (June 30, 2025) (Consistent with December 31, 2024, but higher than 3,506,025 in Q2 2024.)
• $1.18 — Net Loss Per Share (Six Months 2025) (Increased from $0.99 in Six Months 2024.)
• $2.491M — Net Cash Used in Operating Activities (Six Months 2025) (Increased from $0.213M used in Six Months 2024.)

Key Players & Entities

• STRATA Skin Sciences, Inc. (company) — registrant
• XTRAC (company) — excimer laser system product
• Pharos (company) — excimer laser system product
• TheraClear Acne Therapy System (company) — acne treatment product
• United States Food and Drug Administration (regulator) — granted clearance for XTRAC
• State of New York Tax Appeals Tribunal (regulator) — issued adverse sales tax decision
• Photomedex India Private Limited (company) — wholly-owned, inactive subsidiary
• United States Securities and Exchange Commission (regulator) — regulates financial reporting

FAQ

Risk Factors

• Supply Chain Disruptions [high — operational]: Global supply chain disruptions, including those impacting noble gas supplies due to the Russia-Ukraine War and potential impacts from Middle East conflicts and increased tariffs, pose a significant risk to STRATA Skin Sciences' operations and ability to procure necessary components.
• Widening Net Loss and Decreasing Cash [high — financial]: The company reported a net loss of $2.489 million for Q2 2025, a substantial increase from $0.099 million in the prior year. For the six months ended June 30, 2025, the net loss was $4.921 million, up from $3.467 million in 2024. Cash and cash equivalents decreased to $5.966 million from $7.261 million at the end of 2024.
• Increased Operating Expenses [medium — financial]: Total operating expenses rose by 19.5% to $6.530 million in Q2 2025, driven by higher selling and marketing expenses ($3.533 million) and general and administrative expenses ($2.911 million). This increase outpaced revenue growth, contributing to the wider net loss.
• Declining Revenues [medium — financial]: Net revenues decreased by 9.0% to $7.663 million for Q2 2025 and by 4.7% to $14.475 million for the first six months of 2025 compared to the prior year periods. This indicates a weakening top-line performance.
• Deteriorating Stockholders' Equity [high — financial]: Total stockholders' equity has significantly decreased from $4.972 million at December 31, 2024, to $0.308 million at June 30, 2025, primarily due to accumulated deficits. This erosion of equity raises concerns about the company's long-term financial health.
• Increased Net Cash Used in Operations [high — financial]: Net cash used in operating activities for the six months ended June 30, 2025, was $2.491 million, a substantial increase from $0.213 million used in the same period of 2024. This indicates a worsening cash burn rate.

Industry Context

STRATA Skin Sciences operates in the medical aesthetics industry, which is characterized by innovation in devices and treatments for dermatological and cosmetic conditions. The market is competitive, with companies focusing on technological advancements, clinical efficacy, and market penetration. Trends include increasing consumer demand for non-invasive procedures and the integration of digital health solutions.

Regulatory Implications

The company's operations are subject to regulatory oversight by bodies like the FDA, particularly concerning the safety and efficacy of its medical devices. Compliance with evolving healthcare regulations and data privacy laws is crucial. Any disruptions in the supply chain for components used in medical devices could also have regulatory implications if it affects product quality or availability.

What Investors Should Do

1. Monitor operating expense trends closely.
2. Analyze revenue drivers and market demand.
3. Assess the company's cash runway and financing needs.
4. Evaluate the impact of supply chain risks.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total loss incurred by the company since its inception. (STRATA Skin Sciences has a significant accumulated deficit of ($253.065 million) as of June 30, 2025, which has led to a substantial reduction in total stockholders' equity.)

Operating lease right-of-use assets

Assets recognized by a lessee under a lease contract, representing the right to use an underlying asset for the lease term. (The company has $1.092 million in operating lease right-of-use assets as of June 30, 2025, reflecting its obligations for leased properties or equipment.)

Contingent consideration

An obligation to transfer additional consideration to an seller contingent upon the occurrence of certain future events. It is often related to acquisitions. (STRATA Skin Sciences has $983,000 in current contingent consideration and $96,000 in long-term contingent consideration as of June 30, 2025, indicating potential future payments related to past transactions.)

Deferred revenues

Revenue that has been received by the company but not yet earned. It represents a liability until the goods or services are delivered. (The company has $2.372 million in deferred revenues as of June 30, 2025, suggesting future revenue recognition from services or products already paid for.)

Year-Over-Year Comparison

STRATA Skin Sciences reported a deteriorating financial performance compared to the prior year. Net revenues declined by 9.0% in Q2 2025 and 4.7% year-to-date. The net loss widened substantially from $0.099 million to $2.489 million in Q2 2025, and operating expenses increased by 19.5%. Cash and cash equivalents decreased, and total stockholders' equity saw a significant drop, indicating increased financial pressure.

Key Financial Figures

• $0.001 — ange On Which Registered Common Stock, $0.001 Par Value SSKN The Nasdaq Stock Mar
• $7.0 thousand — gible employers could qualify for up to $7.0 thousand of credit for each employee based on qu

Filing Documents

• ef20050400_10q.htm (10-Q) — 1204KB
• ef20050400_ex31-1.htm (EX-31.1) — 13KB
• ef20050400_ex31-2.htm (EX-31.2) — 12KB
• ef20050400_ex32-1.htm (EX-32.1) — 7KB
• 0001140361-25-030939.txt ( ) — 7020KB
• sskn-20250630.xsd (EX-101.SCH) — 52KB
• sskn-20250630_def.xml (EX-101.DEF) — 288KB
• sskn-20250630_lab.xml (EX-101.LAB) — 476KB
• sskn-20250630_pre.xml (EX-101.PRE) — 301KB
• sskn-20250630_cal.xml (EX-101.CAL) — 42KB
• ef20050400_10q_htm.xml (XML) — 1181KB

Financial Statements

Financial Statements: Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (unaudited) 4 Notes to Condensed Consolidated Financial Statements (unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3. Quantitative and Qualitative Disclosure about Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30 Part II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 5. Other Information 31 Item 6. Exhibits 32

Signatures

Signatures 33 Certifications Table of Contents

- Financial Information

PART I - Financial Information ITEM 1.

Financial Statements

Financial Statements STRATA Skin Sciences, Inc. and Subsidiary Condensed Consolidated Balance Sheets As of June 30, 2025 and December 31, 2024 (in thousands, except share and per share data) June 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 5,966 $ 7,261 Restricted cash — 1,334 Accounts receivable, net of allowance for credit losses of $ 604 and $ 433 at June 30, 2025 and December 31, 2024, respectively 4,022 5,253 Inventories 3,236 2,246 Prepaid expenses and other current assets 550 501 Total current assets 13,774 16,595 Property and equipment, net 8,604 10,061 Operating lease right-of-use assets 1,092 1,264 Intangible assets, net 4,363 5,348 Goodwill 2,658 2,658 Other assets 231 231 Total assets $ 30,722 $ 36,157 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,945 $ 2,433 Accrued expenses and other current liabilities 7,401 8,593 Deferred revenues 2,372 2,241 Current portion of operating lease liabilities 303 328 Current portion of contingent consideration 983 1,030 Total current liabilities 14,004 14,625 Long-term debt, net 15,270 15,192 Deferred revenues and other liabilities 264 353 Operating lease liabilities, net of current portion 780 919 Contingent consideration, net of current portion 96 96 Total liabilities 30,414 31,185 Commitments and contingencies (Note 13 ) Stockholders' equity: Series C convertible preferred stock, $ 0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding — — Common stock, $ 0.001 par value; 150,000,000 shares authorized; 4,171,161 shares issued and outstanding at both June 30, 2025 and December 31, 2024 4 4 Additional paid-in capital 253,369 253,112 Accumulated deficit ( 253,065 ) ( 248,144 ) Total stockholders' equity 308 4,972 Total liabilities and stockholders' equit

View Full Filing

View this 10-Q filing on SEC EDGAR